Soon after introducing recombinant hepatitis B virus (HBV) vaccine, universal neonatal VACCINATION became the corner stone of the preventive measures for this potentially life threatening infection (1-3). By 2006 more than 177 out of 193 member states of world health organization (WHO) introduced HBV VACCINATION in their national infant immunization programs (1). Following a complete series of VACCINATION during neonatal period, protective antibody level raises in more than 95% of infant’s blood test up to 18 months after VACCINATION (3-5).The effectiveness of this strategy has been shown by several investigators in reducing the incidence of HBV carrier rate and probably cirrhosis and hepatocellular carcinoma (1, 2, 5-7).

Dear Editor: Planning and implementing mass VACCINATION is important and challenging in regard to the control of Coronavirus disease 2019 (COVID-19). 1-4 In addition to traditional points of dispensing, such as clinics or hospitals, high-throughput large venues, such as arenas, have been used to rapidly immunize a large number of people in many countries. 5-7 Since the COVID-19 outbreak that occurred in May 2021, Taiwan has been racing to vaccinate as many citizens as possible. . .